The DOI matches its Crossref record.
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization
Abstract
A diversity of nicotinic acetylcholine receptor (nAChR) subtypes has been identified in mammalian brain using recombinant DNA technology. Alterations in the activity of these acetylcholinegated ion channels have been implicated in a number of central nervous system disorders including Alzheimer's disease (AD). The potential therapeutic usefulness of (-)-nicotine [(S)-3-(1-methyl-2-pyrrolidinyl) pyridine], the prototypic agonist at nAChRs, is severely limited by side effects that are the result of activation of both cholinergic and noncholinergic pathways in the central and peripheral nervous systems. This study sought to determine the in vitro selectivity of (S)-3-methyl-5-(1methyl-2-pyrrolidinyl)isoxazole (ABT 418), a novel analog of (-)-nicotine in which the pyridine ring was replaced with an isoxazole bioisotere, to activate nAChRs. ABT 418 was a potent inhibitor of [3H]-cytisine binding to nAChR in rat brain (Ki = 3 nM) but was inactive (Ki > 10,000 nM) in 37 other receptor/neurotransmitter-uptake/enzyme/transduction system binding assays, including those for alpha-bungarotoxin, muscarinic and 5-hydroxytryptamine3 receptors. In PC12 cells, patch-clamp studies indicated that ABT 418 was an agonist with an EC50 value of 209 microM, a potency to activate cholinergic channel currents some 4-fold less than that of (-)-nicotine (52 microM). Channel current responses elicited by ABT 418 were prevented by the cholinergic channel blocker, mecamylamine. ABT 418 was also approximately 10-fold less potent (EC50 value = 380 nM) than (-)-nicotine (40 nM) in increasing [3H]-dopamine release from rat striatal slices, an effect that was blocked by the nAChR antagonist, dihydro-beta-erythroidine (10 microM).2+ In contrast, ABT 418 appeared equipotent with (-)-nicotine in enhancing 86Rb+ flux from mouse thalamic synaptosomes. ABT 418 demonstrated an in vitro pharmacological profile of cholinergic channel activation that was robust at some nAChR, but not others. The reasons for this are unclear. However, a nAChR subtype selectivity may account for the in vitro potency differences of ABT 418 on various neurotransmitter systems, and the substantial separation between the cognitive enhancement/anxiolytic benefits, and the reduced central nervous system side-effect liabilities seen in vivo. ABT 418 represents the first neuronal nAChR ligand that differentiates the toxicities/liabilities and other negative aspects normally associated with liabilities and other negative aspects normally associated with (-)-nicotine from the potential pharmacological benefits of selective cholinergic channel activation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an α4β2 nAChR agonist, ABT-418, was found to increase open arm time in the EPM and both ABT-418 and an α4β2 nAChR partial agonist, ABT-089, reversed the anxiogenic effects of nicotine withdrawal (Brioni et al., 1994; Decker et al., 1994; Yohn, Turner, & Blendy, 2014).”
From Nicotine addiction and psychiatric disorders (2015) · cites this paper as Decker et al., 1994
Citations
Cited by
Sorted by citations
Items 101–178 of 178
Segall, M., Champness, E., Leeding, C., et al. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci2003208 · Cited by 32
Oyaizu, M., & Narahashi, T. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01077-x · Cited by 30
Kroker, K. S., Rast, G. F., & Rosenbrock, H. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.167 · Cited by 31
Stimulation of the α4β2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice
Wildeboer, K. M., & Stevens, K. E. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.007 · Cited by 30
Sihver, W., Fasth, K., Ögren, M., Lundqvist, H., Bergström, M., Watanabe, Y., Långström, B., & Nordberg, A. K. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(99)00034-7 · Cited by 30
Isoxazoles: synthesis, evaluation and bioinformatic design as acetylcholinesterase inhibitors
Gutiérrez, M., Matus, M. F., Poblete, T., Amigo, J., Vallejos, G. A., & Astudillo, L. A. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12180 · Cited by 29
“Moreover, the goal of the search for new inhibitors aims has a decline in side effects showed by the current drugs used in the treatment of this disease;([24,25]) as well as based in previous reports for compounds with isoxazolic ring as effective drugs in other diseases treatments with low side effects.([26,27]) It i…”
BackgroundElliott, R. L., Ryther, K. B., Anderson, D. J., Piattoni-Kaplan, M., Kuntzweiler, T. A., Donnelly‐Roberts, D. L., Arnerić, S. P., & Holladay, M. W. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)10080-4 · Cited by 29
Recent developments in neuronal nicotinic acetylcholine receptor modulators
Lin, N., & Meyer, M. D. (1998) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.8.8.991 · Cited by 29
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation
Mohamed, T. S., Jayakar, S. S., & Hamouda, A. K. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00071 · Cited by 27
“ABT-418 is a full nAChR agonist with apparent selectivity for the neuronal nAChR especially the α4β2 subtype (Decker et al., 1994).”
BackgroundEpibatidine: From Frog Alkaloid to Analgesic Clinical Candidates. A Testimonial to “True Grit”!
Williams, M. J., Garraffo, H. M., & Spande, T. F. (2009) · Heterocycles · doi:10.3987/rev-08-sr(d)5 · Cited by 27
Jučaitė, A., Öhd, J., Potter, A., Jaeger, J., Karlsson, P., Hannesdóttir, K., Boström, E., NEWHOUSE, P. A., & Paulsson, B. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3116-7 · Cited by 25
Tani, Y., Saito, K., Tsuneyoshi, A., Imoto, M., & Ohno, T. (1997) · Psychopharmacology · doi:10.1007/s002130050184 · Cited by 25
Huang, C.-S., Yan, J. J., Marszalec, W., & Narahashi, T. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00074-3 · Cited by 23
Arnerić, S. P., Holladay, M. W., & Sullivan, J. P. (1996) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.5.1.79 · Cited by 24
Self-citationABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity
Brioni, J. D., Kim, D. J. B., Brodie, M. S., Decker, M. W., & Arnerić, S. P. (1995) · Psychopharmacology · doi:10.1007/bf02245851 · Cited by 23
Self-citationComparative pharmacology of nicotine and ABT-418, a new nicotinic agonist
Damaj, M. I., Creasy, K. R., Welch, S. P., Rosecrans, J. A., Aceto, M. D. G., & Martin, B. R. (1995) · Psychopharmacology · doi:10.1007/bf02245822 · Cited by 23
Strain-dependent effects of cognitive enhancers in the mouse
Sunyer, B., Patil, S. S., Frischer, C., Hoeger, H., & Lübec, G. (2007) · Amino Acids · doi:10.1007/s00726-007-0511-6 · Cited by 22
“(R)-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride (SIB-1553A) is a neuronal Acetylcholine receptor ligand with agonist selectivity for b4-subunit containing human neuronal Acetylcholine receptors (Decker et al., 1994).”
Background2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands
Elliott, R. L., Kopecka, H., Gunn, D., et al. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00416-7 · Cited by 22
Self-citationO'Neill, A. B., Morgan, S. J., & Brioni, J. D. (1998) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1997.3803 · Cited by 22
Self-citationChronic nicotine-induced improvement of spatial working memory and D2 dopamine effects in rats
Levin, E. D., Christopher, N. C., Briggs, S. J., & Auman, J. T. (1996) · Drug Development Research · doi:10.1002/(sici)1098-2299(19960901)39:1 · Cited by 19
Takechi, K., Suemaru, K., Kiyoi, T., Tanaka, A., & Araki, H. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.021 · Cited by 21
Phenyl pyrrolidine analogues as potent nicotinic acetylcholine receptor (nAChR) ligands
Elliott, R. L., Ryther, K. B., Anderson, D. J., Raszkiewicz, J. L., Campbell, J. E., Sullivan, J. P., & Garvey, D. S. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00154-l · Cited by 21
Self-citationBisson, W. H., Scapozza, L., Westera, G., Mu, L., & Schubiger, P. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040881a · Cited by 21
Efange, S. M. N., Tu, Z., von Hohenberg, K., Francesconi, L. C., Howell, R. C., Rampersad, M. V., TODARO, L. J., Papke, R. L., & Kung, M. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010129z · Cited by 21
Crestini, A., Carbone, E., Rivabene, R., Ancidoni, A., Rosa, P., Tata, A. M., Fabrizi, E., Locuratolo, N., Vanacore, N., Lacorte, E., et al. (2024) · Cells · doi:10.3390/cells13030237 · Cited by 20
“The only study investigating PTI-125 (100 mg, 28 days of treatment) [44] reported that the drug was safe and well tolerated, with no drug-related AEs/SAEs observed during the study.”
BackgroundHall, F. S., Markou, A., Levin, E. D., & Uhl, G. R. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06415.x · Cited by 18
Olesen, P. H., Tønder, J. E., Hansen, J. B., et al. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00063-8 · Cited by 18
Böhme, G. A., Letchworth, S. R., Piot, O., Gatto, G. J., Obinu, M. C., Caldwell, W. S., Laville, M., Brunel, P., Pellerin, R., Leconte, J., et al. (2004) · Drug Development Research · doi:10.1002/ddr.10352 · Cited by 17
“Moreover, it has been established that a4b2 nAChR stimulation with selective agonists can lead to pro-cognitive activity in animal models [Decker et al., 1994; Bencherif et al., 1996; Lippiello et al., 1996].”
BackgroundSynthesis and in vivo studies of the stereoisomers of N-[11C]methyl-homoepibatidine
Patt, J. T., Spang, J. E., Buck, A., Cristina, H., Arras, M., Schubiger, P. A., & Westera, G. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(01)00225-6 · Cited by 17
Muscarinic M1-Receptor Agonists
Cutler, N. R., & Sramek, J. J. (1995) · CNS Drugs · doi:10.2165/00023210-199503060-00006 · Cited by 16
Cholinergic Treatments of Alzheimer's Disease
Tsopelas, N. D., & Marin, D. B. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50034-2 · Cited by 15
Chorvat, R. J., Zaczek, R. C., & Brown, B. S. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.4.499 · Cited by 14
Lin, N., He, Y., & Kopecka, H. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00340-i · Cited by 14
Lin, N., Abreo, M. A., Gunn, D., Lebold, S. A., Lee, E. L., Wasicak, J. T., Hettinger, A.-M., Daanen, J. F., Garvey, D. S., Campbell, J. E., et al. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00462-x · Cited by 14
Self-citationArnerić, S. P., Campbell, J. E., Carroll, S., Daanen, J. F., Holladay, M. W., Johnson, P. M., Lin, N., Marsh, K. C., Peterson, B., Qui, Y., et al. (1997) · Drug Development Research · doi:10.1002/(sici)1098-2299(199705)41:1 · Cited by 13
Self-citationLöffler, M., Bubl, B., Huethe, F., Hubbe, U., McIntosh, J. M., Jackisch, R., & Feuerstein, T. J. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.09.018 · Cited by 12
Lin, N., He, Y., Anderson David, J., et al. (1994) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)80396-6 · Cited by 13
Self-citationThe enhancement of contextual fear conditioning by ABT-418
Kenney, J. W., Wilkinson, D. S., & Gould, T. J. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833a5b9d · Cited by 12
“ABT-418 has been found earlier to enhance other forms of learning, such as inhibitory avoidance in rodents (Decker et al., 1994) and attention in both rodents (McGaughy et al.”
Luine, V. N., Mohan, G., Tu, Z., & Efange, S. M. N. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00988-7 · Cited by 13
Depression, smoking, and nicotine: Toward a bioinformational situation by trait model
Gilbert, D. G. (1996) · Drug Development Research · doi:10.1002/(sici)1098-2299(199607/08)38:3/4 · Cited by 25
Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects
NEWHOUSE, P. A. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty189 · Cited by 11
Søkilde, B., Mikkelsen, I., Stensbøl, T. B., et al. (1996) · Archiv der Pharmazie · doi:10.1002/ardp.19963290207 · Cited by 11
Cholinergic receptors and neurodegenerative diseases
Gualtieri, F. (2000) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(99)00021-7 · Cited by 11
Role of the glycoprotein thorns in anxious effects of rabies virus: Evidence from an animal study
Ghassemi, S., Pourbadie, H. G., Prehaud, C. J. N., Lafon, M., & Sayyah, M. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.05.001 · Cited by 10
Storage, S. S., Mandelkern, M. A., Phuong, J., Kozman, M., Neary, M. K., & Brody, A. L. (2013) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2013.07.010 · Cited by 10
“…partial and full agonists at nAChRs result in anxiolytic effects, suggesting that disturbance of brain cholinergic neurotransmission results in these effects (Brioni et al., 1993, 1994; Arneric et al., 1994; Decker et al., 1994; Skoubis et al., 2006; Feuerbach et al., 2009; Turner et al., 2010).”
BackgroundMessi, E., Pimpinelli, F., Andrè, V., Rigobello, C., Gotti, C., & Maggi, R. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.07.025 · Cited by 9
Lin, N., He, Y., Arnerić, S. P., & Sullivan, J. P. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00183-t · Cited by 9
Self-citationPharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine
Rao, T. S., Sacaan, A. I., Menzaghi, F., Reid, R. T., Adams, P. B., Correa, L. D., Whelan, K. T., & Vernier, J. (2004) · Brain Research · doi:10.1016/j.brainres.2003.12.038 · Cited by 9
SYNTHESIS AND EVOLUTION OF NEW ISOXAZOLO-1,4-QUINONES OF BIOLOGIC INTEREST
Hamadi, N. B., & Msaddek, M. (2006) · Heterocyclic Communications · doi:10.1515/hc.2006.12.6.457 · Cited by 8
Neuropharmacological assessment in mice and molecular docking of piperazine derivative LQFM212
Moreira, L. K. D. S., de Brito, A. F., Fontana, C., de Carvalho, F. S., Sanz, G., Vaz, B. G., Lião, L. M., da Rocha, F. F., Verli, H., Menegatti, R., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112827 · Cited by 8
Olesen, P. H., Swedberg, M. D. B., Eskesen, K., et al. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)00347-8 · Cited by 8
Barreiro, E. J., Barreiro, G., Guimarães, C. R. W., et al. (2000) · Journal of Molecular Structure THEOCHEM · doi:10.1016/s0166-1280(00)00508-x · Cited by 8
Bencherif, M., Byrd, G. D., Caldwell, W. S., Hayes, J. R., & Lippiello, P. M. (1997) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1997.tb00331.x · Cited by 7
An efficient synthesis of pharmacologically active derivatives of 1,3,4-oxadiazoles
Kamble, R. R., & Sudha, B. S. (2006) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570430214 · Cited by 7
Acetylcholine: II. Nicotinic Receptors
Besheer, J., & Bevins, R. A. (2004) · Lincoln (University of Nebraska) · Cited by 6
Ganglionic nicotinic acetylcholine receptor activation by the novel agonist ABT‐418
Briggs, C. A., Hughes, M. L., Monteggia, L. M., Giordano, T., Donnelly‐Roberts, D. L., & Arnerić, S. P. (1995) · Drug Development Research · doi:10.1002/ddr.430340107 · Cited by 6
López-Valdés, H. E., & García‐Colunga, J. (2003) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 4
Natural Products as Lead Compounds in Medicinal Chemistry
Barreiro, E. J., Fraga, C. A. M., & Lima, L. M. (2012) · doi:10.1002/9781118260005.ch3 · Cited by 4
Arnerić, S. P., Sullivan, J. P., Decker, M. W., Brioni, J. D., Briggs, C. A., Donnelly‐Roberts, D. L., Marsh, K. C., Rodrigues, A. D., Garvey, D. S., Williams, M. J., et al. (1994) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4615-8149-9_33 · Cited by 4
Self-citationRadioligand Binding Characterization of Neuronal Nicotinic Acetylcholine Receptors
Anderson, D. J. (2008) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0108s43 · Cited by 3
Effects of the cholinergic channel activator ABT-418 on cortical EEG: Comparison with (?)-nicotine
Radek, R. J., Briggs, C. A., Sullivan, J. P., Kang, C. H., & Arnerić, S. P. (1996) · Drug Development Research · doi:10.1002/(sici)1098-2299(199602)37:2 · Cited by 3
Self-citationPreclinical and Clinical Aspects of Nicotinic Acetylcholine Receptor Imaging
Brust, P., Deuther‐Conrad, W., Donat, C. K., Barthel, H., Riss, P. J., Paterson, L. M., Hoepping, A., Sabri, O., & Cumming, P. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_18 · Cited by 5
Noninvasive Exploration of Nicotinic Acetylcholine Receptors In Vivo
Nordberg, A. K. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-57079-7_21 · Cited by 3
Brioni, J. D., Kim, D. J. B., O'Neill, A. B., Brodie, M. S., Decker, M. W., & Arnerić, S. P. (1997) · Drug Development Research · doi:10.1002/(sici)1098-2299(199703)40:3 · Cited by 3
Self-citationABT — 418, a Novel Nicotinic Agonist
Arnerić, S. P., Williams, M. J., Holladay, M. W., Wasicak, J. T., Donnelly‐Roberts, D. L., Anderson, D. J., Pavlik, P. A., Martin, Y. C., Garvey, D. S., Sullivan, J. P., et al. (1994) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-7416-8_10 · Cited by 2
Self-citationAndleeb, H., Gulsevin, A., & Papke, R. L. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00216 · Cited by 2
Nicotinic Therapeutics for Tourette Syndrome and Other Neuropsychiatric Disorders
Shytle, R. D., Silver, A. A., Newman, M. B., & Sanberg, P. R. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-691-1_22 · Cited by 1
Functional screening of α7 nicotinic receptor ligands
Dunlop, J., Peri, R., Terstappen, G. C., & Bowlby, M. R. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.623 · Cited by 1
Cholinergic receptors and neurodegenerative diseases
(2000) · Pharmacochemistry library · doi:10.1016/s0165-7208(00)80004-5 · Cited by 1
Pharmacological Evaluation of Choline on α4β2 Neuronal Nicotinic Acetylcholine Receptors
Bizimana, L. (2015) · The Sydney eScholarship Repository (The University of Sydney)
Surber, B. W., Elliott, R. L., Kopecka, H., et al. (1996) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/(sici)1099-1344(199609)38:9
Upregulation and Functionality of Neuronal Nicotinic Acetylcholine Receptors
Pakkanen, J. S. (2006) · Työväentutkimus Vuosikirja
Nicotinic Acetylcholine Receptors in Alzheimer’s and Parkinson’s Disease
Dineley, K. T. (2014) · The Receptors · doi:10.1007/978-1-4939-1167-7_19
Nicotine : Pharmacology and therapeutic implications in neurodegenerative and psychiatric disorders
Scerri, C. (2005) · OAR@UM (University of Malta)
The Effects of Varenicline on Neurocognitive Function in Non-smokers with Schizophrenia
Kozak, K. (2016) · TSpace (University of Toronto)
Neue Behandlungsansätze bei der Alzheimer-Demenz
Rösler, M., & Heidrich, A. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6400-6_70
Effects of Cotinine and Nicotine on Chromaffin Cell Signalling
Vainío, P. J. (2000) · Työväentutkimus Vuosikirja
Metadata
- Authors
- Decker, M. W., Brioni, J. D., Sullivan, J. P., Buckley, M. J., Radek, R. J., Raszkiewicz, J. L., Kang, C. H., Kim, D. J., Giardina, W. J., & Wasicak, J. T.
- Affiliations
- Abbott (United States) (US)
- ORCID
- Decker, M W
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1994-07
- Volume
- 270
- Issue
- 1
- Pages
- 319-328
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2100773070
- Cited by
- 180
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 1 · 2020: 3 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 8 · 2014: 1 · 2013: 6 · 2012: 6
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- ABT-418, cognitive enhancement, anxiolytic effects, avoidance learning, mecamylamine, elevated plus maze, cortical EEG, cholinergic ligands
- MeSH terms
- Quinolizidine Alkaloids, Alkaloids, Animals, Azocines, Binding, Competitive, Cognition, Corpus Striatum, Dopamine, Ion Channels, Isoxazoles, Kinetics, Male, Nicotine, Parasympathomimetics, Pyrrolidines, Quinolizines, Receptors, Cholinergic, Receptors, Nicotinic, Rubidium, Rubidium Radioisotopes, Anti-Anxiety Agents, Tritium, PC12 Cells, Rats, Sprague-Dawley, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
